Concepedia

Laura L. Fernandes

LL

12

Publications

1.1K

Citations

11

H-Index

2012

Active since

Affiliations

United States Food and Drug Administration(Current)

Center for Drug Evaluation and Research

University of Michigan

Center for Devices and Radiological Health

Laura L. Fernandes is an author at United States Food and Drug Administration specializing in medicine, adaptive radiotherapy, and clinical trials.

ORCID

Top concepts

Publications per year

2012–2023

12

Publications

12

Analysis of the Association Between Adverse Events and Outcome in Patients Receiving a Programmed Death Protein 1 or Programmed Death Ligand 1 Antibody

V. Ellen Maher, Laura L. Fernandes, Chana Weinstock et al. · Journal of Clinical Oncology · 2019 · 336 citations

FDA Approval Summary: Atezolizumab or Pembrolizumab for the Treatment of Patients with Advanced Urothelial Carcinoma Ineligible for Cisplatin-Containing Chemotherapy

Daniel L. Suzman, Sundeep Agrawal, Yang-Min Ning et al. · The Oncologist · 2018 · 199 citations · Full text

FDA Approval Summary: Rucaparib for the Treatment of Patients with Deleterious <i>BRCA</i> Mutation–Associated Advanced Ovarian Cancer

Sanjeeve Balasubramaniam, Julia A. Beaver, Sara Horton et al. · Clinical Cancer Research · 2017 · 158 citations

FDA Approval Summary: Alpelisib Plus Fulvestrant for Patients with HR-positive, HER2-negative, PIK3CA-mutated, Advanced or Metastatic Breast Cancer

Preeti Narayan, Tatiana M. Prowell, Jennifer Gao et al. · Clinical Cancer Research · 2020 · 157 citations · Full text

Parotid Glands Dose–Effect Relationships Based on Their Actually Delivered Doses: Implications for Adaptive Replanning in Radiation Therapy of Head-and-Neck Cancer

K.U. Hunter, Laura L. Fernandes, K.A. Vineberg et al. · International Journal of Radiation Oncology*Biology*Physics · 2013 · 74 citations · Full text

, , +11

Rows per page

1–5 of 12